These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29915533)

  • 61. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease.
    McDonnell GV; McMillan SA; Douglas JP; Droogan AG; Hawkins SA
    J Neurol; 1999 Feb; 246(2):87-92. PubMed ID: 10195402
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prodrome in relapsing-remitting and primary progressive multiple sclerosis.
    Wijnands JMA; Zhu F; Kingwell E; Zhao Y; Evans C; Fisk JD; Marrie RA; Tremlett H
    Eur J Neurol; 2019 Jul; 26(7):1032-1036. PubMed ID: 30714270
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis.
    Poddighe S; Murgia F; Lorefice L; Liggi S; Cocco E; Marrosu MG; Atzori L
    Int J Biochem Cell Biol; 2017 Dec; 93():148-155. PubMed ID: 28720279
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The Rao's Brief Repeatable Battery in the study of cognition in different multiple sclerosis phenotypes: application of normative data in a Serbian population.
    Dackovic J; Pekmezovic T; Mesaros S; Dujmovic I; Stojsavljevic N; Martinovic V; Drulovic J
    Neurol Sci; 2016 Sep; 37(9):1475-81. PubMed ID: 27207679
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tumour necrosis factor alpha gene (TNF-alpha) -376 polymorphism in Hungarian patients with primary progressive multiple sclerosis.
    Losonczi E; Bencsik K; Nagy ZF; Honti V; Szalczer E; Rajda C; Illés Z; Mátyás K; Rózsa C; Csépány T; Füvesi J; Vécsei L
    J Neuroimmunol; 2009 Mar; 208(1-2):115-8. PubMed ID: 19201038
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical and laboratory features of primary progressive and secondary progressive MS.
    Bashir K; Whitaker JN
    Neurology; 1999 Sep; 53(4):765-71. PubMed ID: 10489038
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis.
    Cantó E; Reverter F; Morcillo-Suárez C; Matesanz F; Fernández O; Izquierdo G; Vandenbroeck K; Rodríguez-Antigüedad A; Urcelay E; Arroyo R; Otaegui D; Olascoaga J; Saiz A; Navarro A; Sanchez A; Domínguez C; Caminero A; Horga A; Tintoré M; Montalban X; Comabella M
    Mult Scler; 2012 Jul; 18(7):983-90. PubMed ID: 22183936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Reuling IE; Polman CH
    Neurology; 2004 Jul; 63(2):335-9. PubMed ID: 15277630
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Metabolic dysfunctions in multiple sclerosis: implications as to causation, early detection, and treatment, a case control study.
    Senanayake VK; Jin W; Mochizuki A; Chitou B; Goodenowe DB
    BMC Neurol; 2015 Aug; 15():154. PubMed ID: 26311235
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ocrelizumab for the treatment of multiple sclerosis.
    Bigaut K; De Seze J; Collongues N
    Expert Rev Neurother; 2019 Feb; 19(2):97-108. PubMed ID: 30570368
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
    de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
    Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.
    Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P
    Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?
    Schwartz CE; Quaranto BR; Healy BC; Benedict RH; Vollmer TL
    Arch Phys Med Rehabil; 2013 Oct; 94(10):1971-81. PubMed ID: 23727344
    [TBL] [Abstract][Full Text] [Related]  

  • 74. SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
    Malhotra S; Castilló J; Bustamante M; Vidal-Jordana A; Castro Z; Montalban X; Comabella M
    Mult Scler; 2013 Apr; 19(5):524-31. PubMed ID: 22933622
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hemispheric asymmetry measured by texture analysis and diffusion tensor imaging in two multiple sclerosis subtypes.
    Savio S; Hakulinen U; Ryymin P; Hagman S; Dastidar P; Soimakallio S; Elovaara I; Eskola H
    Acta Radiol; 2015 Jul; 56(7):844-51. PubMed ID: 25024438
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.
    Boylan MT; Crockard AD; McDonnell GV; Armstrong MA; Hawkins SA
    J Neurol Sci; 1999 Aug; 167(2):79-89. PubMed ID: 10521545
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Detection and quantification of regional cortical gray matter damage in multiple sclerosis utilizing gradient echo MRI.
    Wen J; Yablonskiy DA; Luo J; Lancia S; Hildebolt C; Cross AH
    Neuroimage Clin; 2015; 9():164-75. PubMed ID: 27330979
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
    Javizian O; Metz LM; Deighton S; Koch MW
    Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort.
    Martinelli-Boneschi F; Esposito F; Scalabrini D; Fenoglio C; Rodegher ME; Brambilla P; Colombo B; Ghezzi A; Capra R; Collimedaglia L; Coniglio G; De Riz M; Serpente M; Cantoni C; Scarpini E; Martinelli V; Galimberti D; Comi G
    Eur J Neurol; 2010 May; 17(5):740-5. PubMed ID: 20067515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.